Related Experiment Video
Updated: May 6, 2026

06:49
A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
Published on: October 6, 2015
19.7K
Patient-reported outcomes in sarcopenia: An ICFSR task force report
Charlotte Beaudart1, David Cella2, Roger A Fielding3
1Clinical Pharmacology and Toxicology Research Unit (URCP), Namur Research Institute for Life Sciences (NARILIS), Department of Biomedical Sciences, Faculty of Medicine, University of Namur, Namur, Belgium.
The Journal of Frailty & Aging
|January 24, 2025
Summary
Patient-reported outcome measures (PROMs) are vital for assessing sarcopenia care. This report reviews current PROMs for sarcopenia, identifying research gaps to improve their use in clinical trials.
Area of Science:
- Gerontology
- Clinical Medicine
- Rehabilitation Science
Background:
- Patient-reported outcome measures (PROMs) are essential for evaluating healthcare quality and patient experience.
- Sarcopenia research increasingly recognizes the value of PROMs to complement objective measures.
- Pharmaceutical industries and regulatory bodies are emphasizing PROMs in clinical trial design.
Purpose of the Study:
- To present validated patient-reported outcome measures (PROMs) for sarcopenia.
- To highlight the current state-of-the-art PROMs applicable in clinical settings.
- To identify research gaps and barriers hindering PROM utilization in sarcopenia clinical trials.
Main Methods:
- A comprehensive review of existing literature on PROMs for sarcopenia.
- Analysis of validated PROMs suitable for clinical application and research.
- Identification of key challenges and future research directions.
Main Results:
- Several validated PROMs for sarcopenia are available for clinical and research use.
- There is a growing recognition of PROMs' importance in sarcopenia assessment.
- Significant research gaps and implementation barriers persist.
Conclusions:
- Validated PROMs are critical tools for advancing sarcopenia research and patient care.
- Addressing identified research gaps is necessary to optimize PROM integration into clinical trials.
- Further development and validation efforts are needed to enhance the utility of PROMs in sarcopenia.

